TG Therapeutics Announces Long-term Follow-up Data from the Phase 2 Trial of Ublituximab in Patients with Multiple Sclerosis
TG Therapeutics Announces Positive Data Safety Monitoring Board Reviews of UNITY-CLL and UNITY-NHL Clinical Trials
Finlay Minerals Announces Closing of Non-Brokered Private Placement of Flow-Through and Non-Flow-Through Units